Definium Therapeutics will use September investor events to spotlight its push in mental health drug development after recent milestones. The company recently r

Definium Therapeutics will use September investor events to spotlight its push in mental health drug development after recent milestones. The company recently reported positive Phase 3 data for DT120 ODT in generalized anxiety disorder and updated Q2 2026 results.